Abstract Library

#2019 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) in the Czech NEN Registry 2009-2016: Histologic Spectrum and Clinicopathological Features

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a group of uncommon, but clinically significant diseases. The data published so far have shown significant regional differences in their incidence and appearance in individual primary sites.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sedláčková E, Barkmanova J, Novak J, Mandys V,

Keywords: registry, gastroenteropancreatic neuroendocrine neoplasms,

#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Grego E, Pellicciari M, Novak L, Ortolani S, Antista M,

Keywords: MEN1 syndrome, MEN1 gene mutation, neuroendocrine tumor,

#1155 Evaluation of Features and Predictors for Long Term Hematologic Toxicity in Neuroendocrine Patients Treated with Peptide Receptor Radionuclide Therapy

Introduction: Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) may offer partial or complete objective response in up to 30% of patients. To deliver treatment in a safe and effective manner, long term adverse events should be considered.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Richter S

Authors: Richter S, Xenocostas A, Sanatani M, Davidson R, Novak K,

Keywords: PRRT,

#389 Czech Neuroendocrine Tumor Registry - 28 Months Results

Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Barkmanova J, Honova H, Louthan O, Sedlackova E, Novak J,

Keywords: NET, registry, database, Czech Republic,

#185 Czech Neuroendocrine Registry - First Results

Introduction: The Czech Neuroendocrine Registry was started in October 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Barkmanova J, Novak J, Vitek P, Sedlackova E, Honova H,

Keywords: neuroendocrine registry, population-based system, neuroendocrine tumors (NETs),